Send to

Choose Destination
Cancer Epidemiol Biomarkers Prev. 2019 Nov 4. pii: cebp.0776.2019. doi: 10.1158/1055-9965.EPI-19-0776. [Epub ahead of print]

Psychotropic medication use and postmenopausal breast cancer risk.

Author information

Department of Biostatistics and Epidemiology, University of Massachusetts Amherst.
Family Medicine and Public Health, University of California - San Diego School of Medicine.
Department of Epidemiology, University of Iowa.
Department of Biostatistics and Epidemiology, University of Massachusetts Amherst


Background Prior studies evaluating psychotropic medications in relation to breast cancer risk are inconsistent and have not separately evaluated invasive and in situ disease. Methods We estimated hazard ratios (HR) and 95% confidence intervals (CI) for the association of psychotropic medication use (any, typical antipsychotics, atypical antipsychotics, lithium) with invasive and in situ breast cancer risk among Women's Health Initiative participants (N=155,737). Results Prevalence of psychotropic medication use was low (n=642; 0.4%). During an average 14.8 (SD 6.5) years of follow-up, 10,067 invasive and 2,285 in situ breast were diagnosed. Any psychotropic medication use was not associated with invasive breast cancer risk compared to non-users (HR 0.82, 95% CI 0.57-1.18). In situ breast cancer risk was higher among "typical" antipsychotic medication users compared with non-users (HR 2.05, 95% CI 0.97-4.30). Conclusions Findings do not support an association of psychotropic medication use with invasive breast cancer risk. The possible elevation in in situ breast cancer risk associated with "typical" antipsychotics could not be explained by differences in screening mammography utilization and merits further study. Impact Our findings contribute to knowledge of the safety profile of psychotropic medications and may be useful to clinicians and patients considering use of these medications.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center